Peringatan Keamanan

Species observed : Human (Man)
Test type: TDLo ( Lowest Published Toxic Dose)
Route of exposure: Subcutaneous
Dose/Duration: 21428mg/kg/15
Toxic Effect:
Skin and appendages: Dermatitis, allergic ( after systemic exposure )

Species observed : Rodent - Rat
Test type: LD50
Route of exposure: Oral
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value

Species observed : Rodent - Rat
Test type: LD50
Route of exposure: Subcutaneous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value

Species observed : Rodent - Rat
Test type: LD50
Route of exposure: Intravenous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value

Species observed : Mammal - Dog
Test type: LD50
Route of exposure: Intravenous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value

Species observed : Mammal - Dog
Test type: LD50
Route of exposure: Subcutaneous
Dose/Duration: >5mg/kg
Toxic Effect: Details of toxic effects not reported other than lethal dose value

Lenograstim

DB13144

biotech approved investigational

Deskripsi

Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) The pharmacokinetic profile of lenograstim is similar in healthy volunteers and cancer patients with elimination half-life (t½?) values of 2.3 - 3.3 hrs (volunteers); 2.8-7.5 hrs (cancer patients) following sc administration, and 0.8 - 2.1 hrs (volunteers); 1.1 - 4.0 hrs (cancer patients) following iv administration.

Volume Distribusi Apparent distribution volume (Vd area) is approximately 52 ± 5 mL/kg body weight.

Klirens (Clearance) Plasma clearance of lenograstim increased 3-fold (from 50 up to 150 mL/min) during repeated sc dosing.

Absorpsi

During repeated dosing (iv and sc routes), peak serum concentrations (at the end of iv infusion or after sc injection) are proportional to the injected dose. Repeated dosing with lenograstim by the two injection routes results in no evidence of drug accumulation.

Metabolisme

Lenograstim is metabolised to peptides.

Rute Eliminasi

Lenograstim is poorly excreted in urine as intact compound (less than 1% of the dose).

Interaksi Obat

9 Data

Cyclophosphamide	The risk or severity of pulmonary toxicity can be increased when Lenograstim is combined with Cyclophosphamide.
Topotecan	The risk or severity of neutropenia can be increased when Lenograstim is combined with Topotecan.
Vindesine	The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vindesine.
Vinorelbine	The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vinorelbine.
Vincristine	The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vincristine.
Vinblastine	The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vinblastine.
Vintafolide	The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vintafolide.
Vinflunine	The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vinflunine.
Vincamine	The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vincamine.

Target Protein

Granulocyte colony-stimulating factor receptor CSF3R

Referensi & Sumber

Artikel (PubMed)

PMID: 10776839
Dunn CJ, Goa KL: Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs. 2000 Mar;59(3):681-717.

Link

Contoh Produk & Brand

Produk: 0 • International brands: 2

International Brands

Granocyte
Neutrogin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.